Atara Biotherapeutics Beheer

Beheer criteriumcontroles 1/4

De CEO Atara Biotherapeutics is Cokey Nguyen, benoemd in Sep2024, heeft een ambtstermijn van minder dan een jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.28M, bestaande uit 23.7% salaris en 76.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.33% van de aandelen van het bedrijf, ter waarde $ 215.76K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.2 jaar en 5 jaar.

Belangrijke informatie

Cokey Nguyen

Algemeen directeur

US$2.3m

Totale compensatie

Percentage CEO-salaris	23.7%
Dienstverband CEO	less than a year
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	1.2yrs
Gemiddelde ambtstermijn bestuur	5yrs

Recente managementupdates

Recent updates

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Nov 06

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Sep 06

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Jul 21

Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy

Jul 03

New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

May 14

Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive

May 11

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Feb 06

Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely

Oct 17

Earnings Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 32% Dive

May 18

Need To Know: Analysts Are Much More Bullish On Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Feb 13

Analysts Have Just Cut Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Revenue Estimates By 16%

Nov 22

EMA panel backs approval of Atara's Ebvallo for transplant complication

Oct 14

Analyse CEO-vergoeding

Hoe is Cokey Nguyen's beloning veranderd ten opzichte van Atara Biotherapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$133m
Jun 30 2024	n/a	n/a	-US$181m
Mar 31 2024	n/a	n/a	-US$233m
Dec 31 2023	US$2m	US$540k	-US$276m

Compensatie versus markt: De totale vergoeding ($USD 2.28M ) Cokey } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 649.07K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Cokey te vergelijken met de prestaties van het bedrijf.

CEO

Cokey Nguyen (51 yo)

less than a year

Tenure

US$2,277,691

Compensatie

Dr. Anhco Nguyen, Ph D., also known as Cokey, has been the President, Chief Executive Officer and Director of Atara Biotherapeutics Inc. since September 09, 2024. He served as Chief Scientific Officer at A...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Anhco Nguyen	President	less than a year	US$2.28m	0.33% $ 215.8k
Eric Hyllengren	Executive VP	1.6yrs	geen gegevens	0.19% $ 128.2k
Alex Chapman	Vice President of Corporate Communications & Investor Relations	no data	geen gegevens	geen gegevens
Jill Henrich	Executive VP & Chief Regulatory officer	4.2yrs	geen gegevens	0.16% $ 106.3k
Rajani Dinavahi	Senior VP & Chief Medical Officer	less than a year	geen gegevens	geen gegevens

1.2yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ATRA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.2 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Anhco Nguyen	President	less than a year	US$2.28m	0.33% $ 215.8k
William Heiden	Independent Director	9yrs	US$237.23k	0.11% $ 69.7k
Matthew Fust	Independent Director	10.7yrs	US$239.73k	0.036% $ 23.9k
Carol Gallagher	Lead Independent Director	11.8yrs	US$260.23k	0.29% $ 193.9k
Gregory Ciongoli	Independent Director	less than a year	geen gegevens	geen gegevens
Ameet Mallik	Independent Director	3.3yrs	US$219.52k	0.014% $ 9.4k
Maria Roncarolo	Independent Director	4.5yrs	US$229.73k	0.022% $ 14.5k
Pascal Touchon	Chairman of the Board	5.4yrs	US$4.38m	0.49% $ 325.0k

5.0yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ATRA wordt beschouwd als ervaren (gemiddelde ambtstermijn 5 jaar).

Atara Biotherapeutics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer

Insufficient new directors

Atara Biotherapeutics, Inc. Announces CEO Changes, Effective September 9, 2024

President notifies of intention to sell stock

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2024

Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024

Recent updates

New minor risk - Profitability

Consensus revenue estimates increase by 14%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Atara Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million.

Insufficient new directors

Consensus revenue estimates decrease by 15%, EPS upgraded

Consensus EPS estimates fall by 52%, revenue upgraded

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Atara Biotherapeutics, Inc. Announces CEO Changes, Effective September 9, 2024

New major risk - Share price stability

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Price target decreased by 71% to US$30.33

Atara Biotherapeutics Announces U.S. Fda Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-Cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy

New major risk - Financial position

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

President notifies of intention to sell stock

Consensus revenue estimates increase by 17%

New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2024

Consensus revenue estimates increase by 117%

Price target decreased by 13% to US$4.20

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Atara Biotherapeutics, Inc. Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology

Consensus revenue estimates increase by 50%

Atara Biotherapeutics, Inc. has announced a Derivatives Offering in the amount of $15 million.

Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024

Atara Biotherapeutics, Inc. Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Price target increased by 17% to US$4.83

Consensus revenue estimates increase by 33%

Independent Director recently bought US$101k worth of stock

Consensus revenue estimates decrease by 27%

Price target decreased by 57% to US$6.40

Atara Biotherapeutics, Inc. Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings released

New major risk - Revenue and earnings growth

Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely

Atara Biotherapeutics, Inc. Announces Plans to Submit Tab-cel® BLA in Second Quarter 2024 Following FDA Agreement on Comparability

New major risk - Share price stability

Price target decreased by 8.1% to US$14.82

Consensus revenue estimates decrease by 23%, EPS upgraded

New major risk - Revenue and earnings growth

Price target increased by 15% to US$18.48

Atara Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Financial position

Consensus revenue estimates fall by 21%

Atara Biotherapeutics, Inc. Announces Resignation of Beth Seidenberg from the Board of Directors

Insufficient new directors

Price target decreased by 13% to US$16.13

President recently sold US$61k worth of stock

Earnings Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 32% Dive

Consensus revenue estimates fall by 55%

Consensus revenue estimates fall by 61%

Price target decreased by 20% to US$14.74

Price target decreased by 13% to US$16.43

Atara Biotherapeutics, Inc. Announces Executive Changes

Consensus revenue estimates decrease by 11%, EPS upgraded

Need To Know: Analysts Are Much More Bullish On Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Full year 2022 earnings: EPS and revenues miss analyst expectations